FDA
-
-
-
-
-
-
-
Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen
-
-
-
-
-
-
-
Replimune stock tumbles 20% after FDA raises efficacy concerns
-
-
-
-
-
-
-
JPMorgan Upgrades Replimune Group (REPL) to Neutral
-
-
-
-
-
-
-
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
-
-
-
-
-
-
-
Replimune (REPL) gets CRL from FDA
-
-
-
-
-
-
-
H.C. Wainwright Upgrades Replimune Group (REPL) to Buy
-
-
-
-
-
-
-
Replimune meets with FDA on melanoma treatment application
-
329,906 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

